explore -WSS

explore

author：focus 2025-10-01 00:46:09 - browse：75294

The Novartis booth at ESMO in Madrid. — The Novartis booth at ESMO 2023 in Madrid. Andrew Joseph/STAT

MADRID — Results presented Monday could expand the use of a Novartis therapy for metastatic prostate cancer, moving it from a treatment used after chemotherapy to one with demonstrated benefits beforehand as well.

The Phase 3 data, highlighted in a prime session here at the annual meeting of the European Society for Medical Oncology, also amount to another win for cancer therapies designed to deliver radiation directly to tumor cells. It’s a field that Novartis has poured investments into, and that is attracting interest from other pharma companies.

The trial, called PSMAfore, enrolled patients with a type of metastatic prostate cancer whose disease had started to progress after taking a drug known as an androgen receptor pathway inhibitor, or ARPI. Patients were randomized to either receive a different ARPI or Novartis’ therapy, Pluvicto.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How to save PrEP access — and even expand it
Next article： How a billionaire couple greased the skids for Pelosi’s drug pricing bill

focus

explore

leisure time

WSS

Wearables generate powerful data but its not useful to doctors, yet

Second House panel advances two

Telehealth startups are trying to fill the menopause care vacuum

How a billionaire couple greased the skids for Pelosi’s drug pricing bill

When a patient nears the end, a feared therapy can comfort

How a Boston hospital is priming medical residents to use GPT

hotspot

explore

leisure time

Tori Bowie and the unacceptable rates of Black maternal death

This biotech could one day make human eggs from scratch. But first, they’re trying to rethink IVF

The cancer drug shortage isn’t new — and neither are the solutions

Jan. 6 charges against Trump would add to his mounting legal peril as he campaigns for 2024

State Dept. review finds Biden bears some blame for Afghanistan failures

The stock market has soared this year, but will it last? Experts weigh in

Medicare details structure of new drug price negotiation program

Sanders wants to replace patents with prizes for drug inventions

As demand for Covid shots wanes, Moderna seeks its next success

Headers linked to memory issues, raising questions about soccer safety as the World Cup kicks off

hotspot

The Readout: Lisata, Eisai x Biogen, and the Met Gala (!)

Cytokinetics CEO stresses company can launch heart drug on its own

Mystery swirls around US soldier who entered North Korea days ago, officials say

It's time to retire 'poor historian' from clinicians' vocabularies

HIV vaccine remains elusive. Immunologists keep trying new ideas

Big Tobacco's 'harm reduction': Is it for real, or a sham?

focus

explore

leisure time

Wikipedia